LD-FUD for Highly Aggressive Gastric Cancer

• Status: Recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: All

Summary

A subtype of gastric adenocarcinoma with extensive bone marrow metastasis and DIC has been described. Few patients have been treated properly due to the lack of clinical trials. We designed this phase II study to explore a feasible regimen for this kind of highly aggressive gastric cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
• Treatments: Docetaxel; Fluorouracil

Criteria

Inclusion Criteria:

• Pathologically confirmed gastric adenocarcinoma;

• Bone marrow metastasis confirmed by aspiration, biopsy or PET/CT scan;

• DIC;

• Sufficient liver and renal functions;

Exclusion Criteria:

• treated by cytotoxic or target or I-O drugs;

• insufficient cardiac or pulmonary function;

• active infection;

• no contraceptive measures;